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Small cancer cells don’t stray
W
anderlust is what makes cancer cells deadly. On page 437, Lamouille and Derynck 
show that anticancer drugs already in clinical trials might have an unexpected beneﬁ  t by 
turning the rogue cells into homebodies.
Cancer cells often enlarge and crank up protein synthesis, presumably to support their racing 
metabolism. Before they metastasize, the cells undergo a transformation known as the epithelial–
mesenchymal transition (EMT). They reorganize their skeleton, stretch out, and break connections 
with their neighbors. After they’ve completed the transition, cells dissolve the extracellular matrix that 
restrains them and start spreading. EMT is prodded by increased expression of the cytokine TGF-β 
via the Smad pathway, which regulates gene transcription.
TGF-β also acts through a separate pathway that increases protein synthesis, the researchers 
found while studying cultured breast cancer cells. Dosing the cells with TGF-β spurred them to get 
bigger and boost translation while undergoing EMT.
The speed of protein synthesis is controlled by the mTOR pathway, which Lamouille and Derynck 
found was activated by TGF-β in these cancer cells. In turn, the researchers discovered, mTOR was 
under the control of a pathway initiated by PI3 kinase rather than Smads.
The drug rapamycin, which blocks mTOR, prevented cells from bulking up and boosting protein 
production, but it didn’t forestall EMT. It did, however, rein in the cells, probably by loosening the 
surface attachments that cells use to crawl. These ﬁ  ndings indicate that although tumor cells undergo 
EMT before they move, the two events can be separated.
That distinction suggests a strategy for thwarting metastasis. Researchers have so far focused on 
blocking TGF-β to short-circuit EMT. But drugs that shut down mTOR might keep cancer cells at home even 
if they don’t stop EMT. The researchers are now testing whether rapamycin analogues restrain cancer 
cells in animals. If they do, the good news is that similar compounds are already in clinical trials. 
T
wo key developmental proteins that once appeared to be 
molecular twins perform different jobs and work in differ-
ent parts of the cell, as Geffers et al. show on page 465.
Among its many functions, the Notch pathway helps 
orchestrate the formation of somites that give rise to the 
vertebral column and other structures. The pathway appears to 
be full of redundancy. For example, mice carry four Notch 
genes and three for the Delta proteins that interact with the 
pathway. The jobs of two of the Delta proteins, DLL1 and 
DLL3, have remained unclear. Initial studies suggested that 
the proteins are interchangeable. But individually deleting the 
proteins, which are made in the same part of the mesoderm, 
induces different developmental defects, and a recent study 
suggested that DLL3 interferes with DLL1.
To sort through the confusion, Geffers et al. replaced one or 
both copies of the Dll1 gene with a short but functional version 
of the Dll3 gene. Mice lacking DLL1 die as embryos. The 
researchers found that mice that manufacture DLL3 instead of 
DLL1 also perished during embryogenesis, indicating that one 
protein cannot substitute for the other.
The team also gauged whether one protein inhibits the 
activity of the other by examining mice with three copies of 
Dll3 and one of Dll1. Animals with only one copy of Dll1 
display some skeletal fl  aws. If the proteins were antagonists, 
the scientists reasoned, animals with the extra DLL3 should 
show even more severe 
abnormalities. But these 
mice were no worse off.
The researchers con-
fi   rmed their fi  ndings  by 
tracking Notch after its 
activation. When Notch 
switches on, its intracellu-
lar tail detaches and spirits 
the signal to the nucleus. 
Levels of this tail piece did 
not increase in embryos 
lacking DLL3, the scien-
tists determined. DLL3 
thus does not interfere with 
Notch activation.
So what is DLL3 doing? 
The researchers are still 
not sure, but they discov-
ered that most of the pro-
tein lurked inside the cell, 
mainly in the Golgi apparatus, rather than on the surface, 
where DLL1 resided. The Golgi location suggests that, instead 
of triggering Notch, DLL3 has some other, undiscovered role 
in the pathway. 
Cancer cells (top) exposed to 
TGF-𝗃 grow and elongate as 
they undergo EMT (bottom).
Separate and unequal Deltas
DLL1 (top) studs the surface of the 
cell, whereas DLL3 (bottom) collects 
in the interior.